IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v88y2008i1p62-72.html
   My bibliography  Save this article

Overview of the clinical application of regenerative medicine products in Japan

Author

Listed:
  • Tsubouchi, Mina
  • Matsui, Shigeyuki
  • Banno, Yoshiro
  • Kurokawa, Kiyoshi
  • Kawakami, Koji

Abstract

Objective To identify barriers to the clinical application of regenerative medicine products (RMPs) in Japan.Methods Current Japanese regulatory systems and guidelines were compared with those of the United States (US) and the European Union (EU). A questionnaire was administered to representatives from 23 Japanese companies and 10 research institutes, and an in-person semi-structured interview was conducted with representatives from 10 companies that develop RMP.Results We found that Japan, the US and the EU have similar pre-clinical safety guideline frameworks relating to RMP. However, differences exist between these countries with respect to their review and approval systems and the implementation of guidelines, and these represent major barriers to the clinical application of RMP in Japan. Most companies studied are facing regulatory hurdles such as stringent review processes and regulatory guidelines that do not provide detailed practical examples of the pre-clinical quality and safety data required.Conclusions These results suggest that effective regulatory infrastructure including regulatory systems, guidelines, and communication channels between product developers and regulatory bodies are essential for the prompt clinical application of RMP in Japan.

Suggested Citation

  • Tsubouchi, Mina & Matsui, Shigeyuki & Banno, Yoshiro & Kurokawa, Kiyoshi & Kawakami, Koji, 2008. "Overview of the clinical application of regenerative medicine products in Japan," Health Policy, Elsevier, vol. 88(1), pages 62-72, October.
    • Handle: RePEc:eee:hepoli:v:88:y:2008:i:1:p:62-72
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0168-8510(08)00059-6
    Download Restriction: Full text for ScienceDirect subscribers only
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:88:y:2008:i:1:p:62-72. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.